aztreonam has been researched along with zithromax in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Hanaki, H; Maseda, H; Nakae, T; Sugimura, M | 1 |
| Juan, C; Maciá, MD; Mena, A; Mulet, X; Oliver, A; Pérez, JL | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chmiel, JF; Forssén, AV; Kim, SH; Moskowitz, SM; Nichols, DP; Nick, JA; Saavedra, MT; Saiman, L; Taylor-Cousar, JL | 1 |
| Bratcher, PE; Caceres, SM; Chmiel, JF; Happoldt, CL; Malcolm, KC; Nichols, DP; Nick, JA; Saavedra, MT; Saiman, L; Taylor-Cousar, JL | 1 |
| Cogen, JD; Goss, CH; Heltshe, SL; Nichols, DP; Odem-Davis, K; Ren, CL; Skalland, M; Somayaji, R | 1 |
| Altenburg, J; Bilton, D; Boersma, WG; Chalmers, JD; Crichton, ML; De Soyza, A; Laserna, E; Perea, L; Shoemark, A; Sibila, O | 1 |
1 review(s) available for aztreonam and zithromax
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for aztreonam and zithromax
| Article | Year |
|---|---|
Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Aztreonam; Cystic Fibrosis; Drug Interactions; Female; Forced Expiratory Volume; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin; Young Adult | 2014 |
Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
Topics: Anti-Bacterial Agents; Azithromycin; Aztreonam; Cystic Fibrosis; Drug Administration Routes; Drug Interactions; Drug Monitoring; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Tobramycin; Treatment Outcome; Young Adult | 2017 |
Heterogeneity of treatment response in bronchiectasis clinical trials.
Topics: Anti-Bacterial Agents; Azithromycin; Aztreonam; Bronchiectasis; Humans; Mannitol; Quality of Life | 2022 |
12 other study(ies) available for aztreonam and zithromax
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Outer Membrane Proteins; Down-Regulation; Humans; Macrolides; Membrane Transport Proteins; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing | 2008 |
Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Biofilms; Cefepime; Cephalosporins; Ciprofloxacin; Cystic Fibrosis; DNA-Binding Proteins; Humans; Membrane Proteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; MutS DNA Mismatch-Binding Protein; Pseudomonas aeruginosa; Transcription Factors | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Aztreonam; Child; Cohort Studies; Cystic Fibrosis; Female; Humans; Male; Pseudomonas aeruginosa; Retrospective Studies; Tobramycin; Young Adult | 2020 |